Novel "second-generation" approaches for the control of type 2 diabetes

J Med Chem. 2004 Aug 12;47(17):4111-2. doi: 10.1021/jm030626a.
No abstract available

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl Peptidase 4 / metabolism
  • Glucagon / pharmacology
  • Glucagon / therapeutic use
  • Glucagon-Like Peptide 1
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Hypoglycemic Agents / therapeutic use*
  • Peptide Fragments / pharmacology
  • Peptide Fragments / therapeutic use
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use
  • Protein Precursors / pharmacology
  • Protein Precursors / therapeutic use
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • Protein Tyrosine Phosphatases / antagonists & inhibitors
  • Receptors, Cytoplasmic and Nuclear / agonists
  • Transcription Factors / agonists

Substances

  • Hypoglycemic Agents
  • Peptide Fragments
  • Protease Inhibitors
  • Protein Precursors
  • Receptors, Cytoplasmic and Nuclear
  • Transcription Factors
  • Glucagon-Like Peptide 1
  • Glucagon
  • PTPN1 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • Protein Tyrosine Phosphatases
  • Dipeptidyl Peptidase 4